JPH09505581A - イノシトール三燐酸エステルの炎症性障害治療への使用 - Google Patents
イノシトール三燐酸エステルの炎症性障害治療への使用Info
- Publication number
- JPH09505581A JPH09505581A JP7514993A JP51499395A JPH09505581A JP H09505581 A JPH09505581 A JP H09505581A JP 7514993 A JP7514993 A JP 7514993A JP 51499395 A JP51499395 A JP 51499395A JP H09505581 A JPH09505581 A JP H09505581A
- Authority
- JP
- Japan
- Prior art keywords
- inositol
- triphosphate
- tissue damage
- myo
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 title claims description 16
- 208000027866 inflammatory disease Diseases 0.000 title claims description 12
- 230000000451 tissue damage Effects 0.000 claims abstract description 26
- 231100000827 tissue damage Toxicity 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- -1 inositol triphosphate ester Chemical class 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 15
- 229940048102 triphosphoric acid Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 206010030113 Oedema Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 3
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 abstract description 2
- 102000004506 Blood Proteins Human genes 0.000 abstract description 2
- 108010017384 Blood Proteins Proteins 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 abstract description 2
- 210000002565 arteriole Anatomy 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 210000001736 capillary Anatomy 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 210000000264 venule Anatomy 0.000 abstract description 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 23
- 239000001226 triphosphate Substances 0.000 description 22
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 19
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 229960000367 inositol Drugs 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 235000011178 triphosphate Nutrition 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- GKDKOMAJZATYAY-GCVPSNMTSA-N [(1r,2s,4r,5r)-2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1O GKDKOMAJZATYAY-GCVPSNMTSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000005024 alkenyl aryl group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000005499 phosphonyl group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XJAILBPEAYQACO-UHFFFAOYSA-N 4-acetyloxybutanoyl 4-acetyloxybutanoate Chemical compound CC(=O)OCCCC(=O)OC(=O)CCCOC(C)=O XJAILBPEAYQACO-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- CDAISMWEOUEBRE-JMVOWJSSSA-N cis-inositol Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-JMVOWJSSSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- XHDPYSCXPWDZQX-UHFFFAOYSA-N ethyl-di(propan-2-yl)azanium;hydrogen phosphate Chemical compound OP([O-])([O-])=O.CC[NH+](C(C)C)C(C)C.CC[NH+](C(C)C)C(C)C XHDPYSCXPWDZQX-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- CDAISMWEOUEBRE-GNIYUCBRSA-N muco-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-GNIYUCBRSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. イノシトール三燐酸エステルの、人間を含む哺乳動物の炎症性障害の予防 、緩和または克服のための薬剤の調製への使用。 2. イノシトール三燐酸エステルの、人間を含む哺乳動物の組織損傷の予防、 緩和または克服のための薬剤の調製への使用。 3. 上記イノシトール三燐酸エステルが塩の形態をとっている、請求項1及び 2のいずれか1つに記載の使用。 4. 上記イノシトール三燐酸エステルが、ナトリウム、カルシウム、亜鉛、又 はマグネシウムの塩か、これらの塩の2種類以上を混合したものである、請求項 3に記載の使用。 5. 上記イノシトール三燐酸エステルが、ミオ−イノシトール三燐酸のエステ ルである、請求項1及び2のいずれか1つに記載の使用。 6. 上記イノシトール三燐酸エステルが、D−ミオ−イノシトール−1,2, 6−三燐酸のエステルである、請求項1及び2のいずれか1つに記載の使用。 7. 上記薬剤が、錠剤、顆粒剤、カプセル、溶液又は懸濁液を含む単位剤形を とっている、請求項1乃至6のいずれか1つに記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303854A SE503122C2 (sv) | 1993-11-22 | 1993-11-22 | Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd |
SE9303854-5 | 1993-11-22 | ||
PCT/SE1994/001095 WO1995014477A1 (en) | 1993-11-22 | 1994-11-18 | The use of an ester of inositoltrisphosphate for the treatment of inflammatory conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09505581A true JPH09505581A (ja) | 1997-06-03 |
JP4172045B2 JP4172045B2 (ja) | 2008-10-29 |
Family
ID=20391829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51499395A Expired - Fee Related JP4172045B2 (ja) | 1993-11-22 | 1994-11-18 | イノシトール三燐酸エステルを使用した炎症性障害治療用薬剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5866557A (ja) |
EP (1) | EP0730460B1 (ja) |
JP (1) | JP4172045B2 (ja) |
AT (1) | ATE218871T1 (ja) |
AU (1) | AU1081795A (ja) |
DE (1) | DE69430813T2 (ja) |
DK (1) | DK0730460T3 (ja) |
ES (1) | ES2177620T3 (ja) |
SE (1) | SE503122C2 (ja) |
WO (1) | WO1995014477A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509900A (ja) * | 2000-09-22 | 2004-04-02 | オーファン メディカル,インコーポレイティド | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9600194D0 (sv) * | 1996-01-19 | 1996-01-19 | Perstorp Ab | A new chemical compound |
CA2430190A1 (en) | 2000-11-21 | 2002-05-30 | Alexis Traynor-Kaplan | Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
FR2828206B1 (fr) * | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
AU2003231157C1 (en) | 2002-04-29 | 2009-02-26 | Normoxys, Inc. | Inositol pyrophosphates, and methods of use thereof |
FI20021570A0 (fi) * | 2002-09-03 | 2002-09-03 | Gallen Kallela Siren Janne | Päällystetyn kirurgisen stentin paranneltu rakenne |
US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
US20050130897A1 (en) * | 2003-12-11 | 2005-06-16 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
US7745423B2 (en) * | 2004-07-06 | 2010-06-29 | NormOxys, Inc | Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
US20060106000A1 (en) * | 2004-07-06 | 2006-05-18 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
US20060258626A1 (en) * | 2004-07-06 | 2006-11-16 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
CA2601641A1 (en) * | 2005-03-18 | 2006-09-28 | Oxyplus, Inc. | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin |
JP2010514772A (ja) * | 2006-12-29 | 2010-05-06 | ノームオクシス インコーポレイテッド | シクリトールおよびその誘導体ならびにその治療用途 |
US20080312138A1 (en) * | 2007-05-01 | 2008-12-18 | Claude Nicolau | Erythropoietin complementation or replacement |
US20080287341A1 (en) * | 2007-05-18 | 2008-11-20 | Danyang Chen | Treatment of vascular abnormalities using nanoparticles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
SE465951B (sv) * | 1984-10-23 | 1991-11-25 | Perstorp Ab | Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav |
SE8605063D0 (sv) * | 1986-11-26 | 1986-11-26 | Matti Siren | Derivatives of cyclohexane |
SE464059C (sv) * | 1988-09-15 | 1997-06-02 | Perstorp Ab | Användning av inositoltrifosfat för framställning av läkemedel |
CA2019878A1 (en) * | 1989-09-13 | 1991-03-13 | Robert Sabin | Method of treatment of rheumatoid arthritis using phytic acid |
SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
-
1993
- 1993-11-22 SE SE9303854A patent/SE503122C2/sv not_active IP Right Cessation
-
1994
- 1994-11-18 EP EP95901676A patent/EP0730460B1/en not_active Expired - Lifetime
- 1994-11-18 US US08/640,785 patent/US5866557A/en not_active Expired - Fee Related
- 1994-11-18 JP JP51499395A patent/JP4172045B2/ja not_active Expired - Fee Related
- 1994-11-18 AT AT95901676T patent/ATE218871T1/de not_active IP Right Cessation
- 1994-11-18 WO PCT/SE1994/001095 patent/WO1995014477A1/en active IP Right Grant
- 1994-11-18 DE DE69430813T patent/DE69430813T2/de not_active Expired - Fee Related
- 1994-11-18 AU AU10817/95A patent/AU1081795A/en not_active Abandoned
- 1994-11-18 DK DK95901676T patent/DK0730460T3/da active
- 1994-11-18 ES ES95901676T patent/ES2177620T3/es not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509900A (ja) * | 2000-09-22 | 2004-04-02 | オーファン メディカル,インコーポレイティド | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE69430813T2 (de) | 2003-01-30 |
ES2177620T3 (es) | 2002-12-16 |
JP4172045B2 (ja) | 2008-10-29 |
EP0730460A1 (en) | 1996-09-11 |
DE69430813D1 (de) | 2002-07-18 |
US5866557A (en) | 1999-02-02 |
SE503122C2 (sv) | 1996-03-25 |
SE9303854D0 (sv) | 1993-11-22 |
ATE218871T1 (de) | 2002-06-15 |
AU1081795A (en) | 1995-06-13 |
EP0730460B1 (en) | 2002-06-12 |
SE9303854L (sv) | 1995-05-23 |
DK0730460T3 (da) | 2002-09-23 |
WO1995014477A1 (en) | 1995-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0583863B1 (en) | Use of esters of L-2-oxothiazolidine-4-carboxylate for the manufacture of a medicament for stimulating intracellar synthesis of glutathione | |
US5015634A (en) | Method of treating tissue damage with inositol triphosphate | |
US4066678A (en) | 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof | |
JP4172045B2 (ja) | イノシトール三燐酸エステルを使用した炎症性障害治療用薬剤 | |
JPH05502864A (ja) | 薬剤 | |
CN111770756B (zh) | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 | |
JPH02191217A (ja) | イノシトールトリホスフェートを含有する組織の損傷に対する医薬 | |
US5057507A (en) | Method of alleviating bone damage with inositoltriphosphate | |
US5407924A (en) | Method of treating pain using inositol triphosphate | |
JPH03503162A (ja) | 化学療法における毒性特性の改良 | |
JPH09505580A (ja) | 鎮痛薬剤の調製のためのイノシトール三燐酸エステルの使用 | |
EP1678189A2 (de) | Verfahren zur herstellung von trans- oder cis-diammoniumdichlorodihydroxoplatin (iv)-salzen und -derivaten und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen | |
CN108864114B (zh) | 选择性a2a受体拮抗剂 | |
JPS6016926A (ja) | 抗腫瘍剤 | |
PT97279B (pt) | Processo para a preparacao de derivados de acidos nitrato-alcanocarboxilicos | |
JPS6338322B2 (ja) | ||
NL8203983A (nl) | Fosforamide derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze bevatten. | |
KR100249408B1 (ko) | (s)-2,3-디하이드로폴리프레놀,(s)-2,3-디하이드로폴리프레닐모노포스-페이트,이들의제조방법및이들을포함한암의성장또는전이억제용약제 | |
FI61893C (fi) | Foerfarande foer framstaellning av antiinflammatoriska fenylbutazon-enolesterderivat | |
US3309270A (en) | Organic phosphorus anthelmintics and method of using the same | |
US4443458A (en) | Aminocrotonyl 3,5-dinitropyridine useful as adjuncts to radiation therapy | |
EP4294405A1 (en) | Compositions and compounds for co-delivery of uridine and ketoleucine | |
DE2533930A1 (de) | Transaminomethylcyclohexancarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
EP0666748A1 (en) | The use of inositoltrisphosphate for the preparation of medicaments | |
JPS63258421A (ja) | 糖ラクタムを含有する抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051101 |
|
RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20051101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070731 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080603 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080703 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080811 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080724 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |